Professional Resources


	Home

	Prevalence of Low T

	Symptoms and diagnosis

	Benefits of AndroGel

	Safety and monitoring

	Professional resources

	For your patients

	References

Printer version

Send to a colleague

Text size

The Endocrine Society

The Endocrine Society is an international body with 13,000 members from over 85 countries.

These professionals are dedicated to researching and treating the full range of endocrine disorders: diabetes, reproduction, infertility, osteoporosis, thyroid disease, obesity/lipids, growth hormone, pituitary tumors, and adrenal insufficiency.

The Endocrine Society works to foster a greater understanding of endocrinology among the general public and practitioners of complementary medical disciplines, and to promote the interests of all endocrinologists at the national scientific research and health policy levels of government.

The Endocrine Society has developed treatment guidelines for men with Low T. Click here to view these guidelines.

Additional reading

The following resources can give you additional information on Low T.

American Association of Clinical Endocrinologists (AACE)
1000 Riverside Avenue, Suite 205
Jacksonville, FL 32204
904.353.7878
www.aace.com

American Academy of Family Physicians (AAFP)
11400 Tomahawk Creek Parkway
Leawood, KS 66211-2672
913.906.6000
www.aafp.org

The Endocrine Society
8401 Connecticut Avenue, Suite 900
Chevy Chase, MD 20815
301.941.0200 or 888.363.6274
www.endo-society.org

American Association for Klinefelter Syndrome Information and Support (AAKSIS)
2945 W. Farwell Ave.
Chicago, IL 60645-2925
888.466.KSIS (888.466.5747)
www.aaksis.org

American Diabetes Association (ADA)
1701 North Beauregard Street
Alexandria, VA 22311
800.DIABETES (800.342.2383)
www.diabetes.org

Safety and monitoring

For your patients


		AndroGel is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Androgens are contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate. AndroGel is not indicated for use in women. Geriatric patients treated with androgens may be at an increased risk for the development of prostatic hyperplasia and prostatic carcinoma. The most frequent adverse events reported by ≥5% of patients associated with the consistent use of AndroGel included abnormal lab test, acne, prostate disorder, and application site reaction.

This information is intended for residents of the United States.
For international product information please visit us at http://www.solvay.com.
© 2007 Solvay Pharmaceuticals, Inc.